161 related articles for article (PubMed ID: 9822548)
1. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
Subramanian G; Paterlini MG; Larson DL; Portoghese PS; Ferguson DM
J Med Chem; 1998 Nov; 41(24):4777-89. PubMed ID: 9822548
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of 4-(N,N-diarylamino)piperidines with high selectivity to the delta-opioid receptor: a combined 3D-QSAR and ligand docking study.
Podlogar BL; Poda GI; Demeter DA; Zhang SP; Carson JR; Neilson LA; Reitz AB; Ferguson DM
Drug Des Discov; 2000; 17(1):34-50. PubMed ID: 10928448
[TBL] [Abstract][Full Text] [Related]
3. Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor. A model for receptor activation.
Paterlini G; Portoghese PS; Ferguson DM
J Med Chem; 1997 Sep; 40(20):3254-62. PubMed ID: 9379445
[TBL] [Abstract][Full Text] [Related]
4. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations.
Lavecchia A; Greco G; Novellino E; Vittorio F; Ronsisvalle G
J Med Chem; 2000 Jun; 43(11):2124-34. PubMed ID: 10841791
[TBL] [Abstract][Full Text] [Related]
5. Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists.
Tuthill PA; Seida PR; Barker W; Cassel JA; Belanger S; DeHaven RN; Koblish M; Gottshall SL; Little PJ; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2004 Nov; 14(22):5693-7. PubMed ID: 15482950
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling on kappa opioid receptor and its interaction with nonpeptide kappa opioid agonists.
Liu DX; Jiang HL; Shen JS; Zhu WL; Zhao L; Chen KX; Ji RY
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):131-6. PubMed ID: 10437159
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
[TBL] [Abstract][Full Text] [Related]
8. Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
Kumar V; Guo D; Marella M; Cassel JA; Dehaven RN; Daubert JD; Mansson E
Bioorg Med Chem Lett; 2008 Jun; 18(12):3667-71. PubMed ID: 18487043
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.
Subramanian G; Paterlini MG; Portoghese PS; Ferguson DM
J Med Chem; 2000 Feb; 43(3):381-91. PubMed ID: 10669565
[TBL] [Abstract][Full Text] [Related]
10. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
[TBL] [Abstract][Full Text] [Related]
11. Comparative modeling of human kappa opioid receptor and docking analysis with the peptide YFa.
Patra MC; Kumar K; Pasha S; Chopra M
J Mol Graph Model; 2012 Mar; 33():44-51. PubMed ID: 22172315
[TBL] [Abstract][Full Text] [Related]
12. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
Zhorov BS; Ananthanarayanan VS
Arch Biochem Biophys; 2000 Mar; 375(1):31-49. PubMed ID: 10683246
[TBL] [Abstract][Full Text] [Related]
13. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
Shenderovich MD; Liao S; Qian X; Hruby VJ
Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
[TBL] [Abstract][Full Text] [Related]
14. Building 3D-structural model of kappa opioid receptor and studying its interaction mechanism with dynorphin A(1-8).
Wan XH; Huang XQ; Zhou DH; Jiang HL; Chen KX; Chi ZQ
Acta Pharmacol Sin; 2000 Aug; 21(8):701-8. PubMed ID: 11501178
[TBL] [Abstract][Full Text] [Related]
15. Chemotype-selective modes of action of κ-opioid receptor agonists.
Vardy E; Mosier PD; Frankowski KJ; Wu H; Katritch V; Westkaemper RB; Aubé J; Stevens RC; Roth BL
J Biol Chem; 2013 Nov; 288(48):34470-83. PubMed ID: 24121503
[TBL] [Abstract][Full Text] [Related]
16. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor.
Våbenø J; Nikiforovich GV; Marshall GR
Chem Biol Drug Des; 2006 May; 67(5):346-54. PubMed ID: 16784459
[TBL] [Abstract][Full Text] [Related]
17. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.
Fowler CB; Pogozheva ID; Lomize AL; LeVine H; Mosberg HI
Biochemistry; 2004 Dec; 43(50):15796-810. PubMed ID: 15595835
[TBL] [Abstract][Full Text] [Related]
18. New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands.
Pasquinucci L; Iadanza M; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Parenti C; De Luca L; Ronsisvalle G
Pharmazie; 2007 Nov; 62(11):813-24. PubMed ID: 18065096
[TBL] [Abstract][Full Text] [Related]
19. Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
Przydzial MJ; Pogozheva ID; Ho JC; Bosse KE; Sawyer E; Traynor JR; Mosberg HI
J Pept Res; 2005 Nov; 66(5):255-62. PubMed ID: 16218993
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the conformational requirements for binding to the kappa-opioid receptor and its subtypes. I. Novel alpha-helical cyclic peptides and their role in receptor selectivity.
Collins N; Hruby VJ
Biopolymers; 1994 Sep; 34(9):1231-41. PubMed ID: 7948735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
